Previous 10 | Next 10 |
BAMCO’s 13F portfolio value increased from $27.66B to $32.58B this quarter. Ron Baron decreased Tesla while increasing ZoomInfo Tech during the quarter. Their top five positions are at ~25% of the overall portfolio. For further details see: Tracking Ron Baron's BA...
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with che...
Bilibili Inc.’s (BILI) entertainment platform enables its users to consume and create content. The company has quickly become quite popular as its user base has increased exponentially due to the coronavirus. Bilibili Inc. ( BILI ) is an online entertainment services platform ...
Overview of Five Prime Therapeutics. Focus on the large molecule (biologic) Bemarituzumab, including existing patient need, recent clinical trial results, patent situation and possible competition. Model presented to help estimate potential worldwide sales of Bemarituzumab using R...
SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appointment of Alan Sandler, M.D., to the newly created position of President, He...
Could These Be The Best Biotech Stocks To Buy Or Sell Right Now? Biotech stocks have been in the center of attention for all the right reasons. It is no surprise after all as biotech companies continue to improve the quality of life that we enjoy today. Human beings are living l...
Shares of the clinical-stage biotech Five Prime Therapeutics (NASDAQ: FPRX) are up by a jaw-dropping 364% in pre-market trading Wednesday morning. The biotech's stock is popping in response to positive midstage trial results for the stomach cancer drug candidate bemarituzumab. S...
Five Prime Therapeutics (FPRX) surges 304% on positive topline results from the global Phase 2 FIGHT trial, enrolling 155 patients.The trial compared bemarituzumab (FPA144) in combination with mFOLFOX6 chemotherapy to placebo combined with mFOLFOX6 in patients with fibroblast growth...
All three efficacy endpoints in the global Phase 2 FIGHT trial met pre-specified statistical significance • Median progression-free survival (PFS) improved from 7.4 months in the placebo arm to 9.5 months in the bemarituzumab arm. Hazard ratio (HR) 0.68 (95% CI: 0.44-1.04) p=0....
CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. Shanghai's Zai Lab...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...